Skip to content
Retatrutide Guide

About · Medical review

How Retatrutide Guide is medically reviewed

Health content has consequences. Every page on this site is checked against primary sources, reviewed by a clinician before publication, and re-reviewed on a fixed cadence — or immediately when new evidence lands.

Who reviews this site

Every clinical page on Retatrutide Guide is reviewed by a licensed clinician — typically a Doctor of Pharmacy (PharmD) or a physician with relevant training in endocrinology, obesity medicine, or internal medicine — before publication.

The medical reviewer is named, with verifiable credentials, in the "Reviewed by" line near the top of each article. Reviewer names and affiliations are not anonymous or aggregated; readers are entitled to know who put their professional reputation on each page.

Medical review
Every page on this site is researched against primary sources and held to the review standards described on this page before publication.
An independent Doctor of Pharmacy (PharmD) reviewer is currently being onboarded to verify and sign each page. Until that sign-off begins, articles carry an "Independent medical reviewer onboarding" notice rather than a reviewer name.
Reviewer names are never backfilled: a name appears on a page only after that reviewer has personally reviewed the published content. Latest editorial review pass: April 2026.

What the reviewer checks

  • Every numerical claim is traceable to a peer-reviewed publication, regulatory filing, or registered clinical trial protocol.
  • No page recommends a specific dose, regimen, or course of treatment to a reader. Treatment recommendations are the exclusive domain of a treating clinician.
  • Investigational status is stated clearly on every page that discusses retatrutide's effects.
  • Comparative claims against approved drugs are framed with their actual trial caveats — population, duration, and design differences.
  • No content recommends, endorses, or links to gray-market or unapproved sources of retatrutide.

Review cadence

  • Initial review — every page reviewed and signed off before first publication.
  • Quarterly review — every clinical page re-reviewed every 90 days.
  • Event-triggered review — within 72 hours of a major trial readout, regulatory action, or label change, every affected page is re-reviewed and updated as needed.

The most recent review date is shown at the top of every article. The page's "last updated" date reflects the most recent substantive revision.

Conflicts of interest

Retatrutide Guide does not accept payment, samples, consulting agreements, or other compensation from Eli Lilly, Novo Nordisk, or any other manufacturer of GLP-1-class medications. The site is not affiliated with any pharmaceutical company.

When (and if) the site adopts affiliate or advertising revenue, those commercial relationships will be disclosed site-wide and on the relevant pages. Affiliate links, when present, are marked with rel="sponsored nofollow" at the link level, not just disclosed in fine print.

Corrections

If you find an error, please reach out via the contact page. Substantive corrections receive a dated correction note at the bottom of the affected page. We do not silently rewrite published content.

This site is not medical advice

Retatrutide Guide is informational. Nothing on this site is a substitute for a conversation with a licensed clinician who knows your medical history. Treatment decisions — including any decision to start, stop, or modify a medication — must be made with that clinician. If you are considering changing a treatment plan, talk to your doctor first.